NCT06644183View on ClinicalTrials.gov

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

March 19, 2025

Primary Completion Date

October 1, 2028

Study Completion Date

October 1, 2032

Conditions
LeukemiaRelapsed LeukemiaChronic Lymphocytic LeukemiaRelapsed CancerRefractory Leukemia
Interventions
DRUG

Roginolisib

Phosphoinositide 3-kinase delta inhibitor, 40 mg capsule, taken orally per protocol.

DRUG

Venetoclax

B-cell lymphoma 2 inhibitor, 10, 50, and 100mg tablets, taken orally per standard of care.

DRUG

Rituximab

Chimeric anti-CD 20 monoclonal antibody, single-use 10 and 50mL vials, via intravenous (into the vein) infusion per standard of care.

Trial Locations (1)

02115

RECRUITING

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Jennifer R. Brown, MD, PhD

OTHER